Back to top
more

KALA BIO, Inc. (KALA)

(Delayed Data from NSDQ)

$7.05 USD

7.05
14,951

+0.35 (5.22%)

Updated Nov 6, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kala Pharmaceuticals (KALA) Flat As Market Sinks: What You Should Know

by Zacks Equity Research

Kala Pharmaceuticals (KALA) closed the most recent trading day at $11.90, making no change from the previous trading session.

Gilead (GILD) Reports Positive Data From Urothelial Cancer Study

by Zacks Equity Research

Gilead's (GILD) new and updated positive results from a phase II study show Trodelvy's rapid and durable responses for patients across a range of hard-to-treat types of mUC.

Ultragenyx (RARE) Q4 Earnings Miss, Revenues Increase Y/Y

by Zacks Equity Research

Ultragenyx (RARE) reports a wider loss in the fourth quarter while revenues increase on growth in demand for its drugs.

Kala Pharmaceuticals (KALA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Kala Pharmaceuticals (KALA) closed at $12.99, marking a +1.64% move from the previous day.

Kala Pharmaceuticals (KALA) Stock Moves -0.66%: What You Should Know

by Zacks Equity Research

Kala Pharmaceuticals (KALA) closed the most recent trading day at $16.54, moving -0.66% from the previous trading session.

Kala Pharma (KALA) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Kala Pharma (KALA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Best Momentum Stocks to Buy for January 17th

by Zacks Equity Research

RYAM, BUD and KALA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 17, 2022.

Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More

by Zacks Equity Research

Updates from Gilead Sciences (GILD) and ProQR (PRQR) are the key highlights from the biotech sector during the past week.

Wall Street Analysts Predict a 268% Upside in Kala Pharma (KALA): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Kala Pharma (KALA) points to a 267.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Kala Pharmaceuticals (KALA) Up as FDA Accepts IND for KPI-012

by Zacks Equity Research

The FDA accepts Kala Pharmaceuticals' (KALA) investigational new drug application for pipeline candidate KPI-012 for treating persistent corneal epithelial defect. Stock up.

Entrada (TRDA) Down on Regulatory Update for DMD Candidate

by Zacks Equity Research

Entrada (TRDA) plunges on clinical hold notice from the FDA regarding its Investigational New Drug Application (IND) for Duchenne muscular dystrophy (DMD) candidate.

bluebird's (BLUE) SCD Studies Clinical Hold Lifted by the FDA

by Zacks Equity Research

bluebird (BLUE) announces that the partial clinical hold on studies evaluating lovo-cel for sickle cell disease (SCD) for patients under the age of 18 has now been lifted.

Here's Why Kala Pharma (KALA) Looks Ripe for Bottom Fishing

by Zacks Equity Research

Kala Pharma (KALA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Cigna (CI) Focuses on Enhancing Pharmacy Offerings in 2023

by Zacks Equity Research

Cigna (CI) decides to integrate cost-effective biosimilars within its commercial formularies from next year in a bid to drive pharmacy revenues.

Emergent Biosolutions (EBS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -2,016.67% and 10.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Kala Pharmaceuticals (KALA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Kala Pharma (KALA) delivered earnings and revenue surprises of 13.64% and 18.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AquaBounty Technologies, Inc. (AQB) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 11.11% and 12.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Kala Pharma (KALA) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Kala Pharma (KALA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Kala Pharma (KALA) delivered earnings and revenue surprises of -25% and 55.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 28.57% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Trevena (TRVN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Trevena (TRVN) delivered earnings and revenue surprises of -11.11% and 96.94%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Athenex (ATNX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Athenex (ATNX) delivered earnings and revenue surprises of -50% and 16.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Kala Pharmaceuticals (KALA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kala Pharma (KALA) delivered earnings and revenue surprises of -58.14% and 45.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Kala Pharmaceuticals (KALA) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.